October 27, 2025 How Hormones May Influence Tirzepatide Outcomes Researchers show how reproductive stage and hormone therapy influence weight-loss outcomes in women treated with tirzepatide. Conexiant
October 24, 2025 A New Approach to Lowering Cardiovascular Risk? Researchers evaluated obicetrapib’s effects on lipid levels and cardiovascular outcomes. Conexiant
October 23, 2025 Waist Loss Only Part of Semaglutide’s Power Semaglutide lowered cardiovascular events in patients with overweight or obesity without diabetes, independent of weight loss. Conexiant
October 23, 2025 Same Disease, Different DNA Study finds Chinese heart disease patients have four times more rare genetic variants than UK counterparts The Pathologist
October 22, 2025 Do GLP-1RAs Differ in Cardiometabolic Protection? Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes. Conexiant
October 16, 2025 Comprehensive Review Identifies Key Neonatal Death Risks Review grades evidence on neonatal mortality across 64 reviews; methods and gaps outlined. Conexiant
October 16, 2025 New Criteria, New Numbers on Obesity A Lancet Commission definition integrating BMI with anthropometric measures increased obesity prevalence by ~60% in a major US cohort, identifying previously unrecognized high-risk patients while introducing distinct clinical phenotypes. Conexiant
October 16, 2025 Cardiac Rehab Participation One-Third Lower in Women Women remain underrepresented in cardiac rehabilitation across all stages of participation. Conexiant
October 15, 2025 Study Describes Patterns in Reported Drug Interactions Researchers analyze about 177,000 drug interactions to identify key medication safety trends. Conexiant